Guardant Health, Inc. Forecast, price target & analysts
Guardant Health, Inc. Target price 2025 - Analyst rating & recommendation
Guardant Health, Inc. Classifications & Recommendation:
Guardant Health, Inc. Price Target
| Target Price | $55.45 |
| Price | $42.11 |
| Potential |
31.68%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $55.45.
This is
31.68%
register free of charge
$65.00
54.36%
register free of charge
$20.00
52.51%
register free of charge
|
|
| A rating was issued by 24 analysts: 21 Analysts recommend Guardant Health, Inc. to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
31.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 739.02 | 854.27 |
| 31.04% | 15.60% | |
| EBITDA Margin | -54.29% | -26.70% |
| 41.08% | 50.82% | |
| Net Margin | -59.73% | -42.28% |
| 36.53% | 29.21% |
21 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.56 | -2.91 |
| 16.82% | 18.26% | |
| P/E | negative | |
| EV/Sales | 6.66 |
18 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Guardant Health, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Current Guardant Health, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler | Locked ➜ Locked | Locked | Feb 26 2025 |
| Scotiabank | Locked ➜ Locked | Locked | Feb 24 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 24 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 24 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Feb 21 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Feb 21 2025 |
| Raymond James | Locked ➜ Locked | Locked | Feb 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Raymond James: Locked ➜ Locked
|
Feb 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
